Roivant's Brepocitinib Reports Positive Trial Results in Eye Disease
Roivant reported positive trial results for its immune drug brepocitinib in non-infectious uveitis, an inflammatory eye condition, following its earlier clearance for dermatomyositis.
2newsrooms
2articles
3 hoursrunning
Oct 21first seen
Ask Scout
Scout answers questions about this story using only the coverage below.
Coverage over time
Articles
| Oct 21, 8:31 AM | biopharmadive.com | Roivant, continuing ascent, claims another victory for rare disease drug |
| Oct 21, 5:05 AM | statnews.com | STAT+: Roivant says closely watched immune drug succeeded in new eye disease |